Research programme: Alzheimer's disease immunotherapy - Acumen/Merck

Drug Profile

Research programme: Alzheimer's disease immunotherapy - Acumen/Merck

Alternative Names: ACU 193; anti-ADDL antibodies; HuC 091

Latest Information Update: 08 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Northwestern University
  • Developer Acumen Pharmaceuticals
  • Class Antibodies; Vaccines
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 01 Mar 2018 Preclinical development is ongoing in USA
  • 01 Mar 2018 Acumen Pharmaceuticals entered into a development and clinical manufacturing services agreement with Avid Bioservices for ACU 193
  • 21 Dec 2011 Merck & Co terminates its worldwide license for ADDL monoclonal antibody and vaccine technology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top